Table 4.
Associations of genes expression with AJCC tumour pathologic PT, tumour stage, age and gender in 157 patients with hepatocellular carcinoma
| Factors | No. of patients | ACSM3 | FCN2 | INTS8 | LCAT | MT1G | UBAP2L | ||||||
| High | Low | High | Low | High | Low | High | Low | High | Low | High | Low | ||
| PT | 157 | P = 0.037 | P = 0.026 | P = 0.046 | P = 0.000 | P = 0.016 | P = 0.004 | ||||||
| T1 | 62 (39.5 %) | 39 (62.9 %) | 23 (37.1 %) | 39 (62.9 %) | 23 (37.1 %) | 23 (37.1 %) | 39 (62.9 %) | 45 (72.6 %) | 17 (27.4 %) | 39 (62.9 %) | 23 (37.1 %) | 22 (35.5 %) | 40 (64.5 %) |
| T2 | 40 (25.5 %) | 20 (50.0 %) | 20 (50.0 %) | 13 (32.5 %) | 27 (67.5 %) | 24 (60.0 %) | 16 (40.0 %) | 12 (30.0 %) | 28 (70.0 %) | 13 (32.5 %) | 27 (67.5 %) | 29 (72.5 %) | 11 (27.5 %) |
| T3 | 46 (29.3 %) | 16 (34.8 %) | 30 (65.2 %) | 22 (47.8 %) | 24 52.2 %) | 28 (60.9 %) | 18 (39.1 %) | 18 (39.1 %) | 28 (60.9 %) | 21 (45.7 %) | 25 54.3 %) | 23 (50.0 %) | 23 (50.0 %) |
| T4 | 9 (5.7 %) | 4 (44.4 %) | 5 (55.6 %) | 4 (44.4 %) | 5 (55.6 %) | 4 (44.4 %) | 5 (55.6 %) | 4 (44.4 %) | 5 (55.6 %) | 6 (66.7 %) | 3 (33.3 %) | 5 (55.6 %) | 4 (44.4 %) |
| Stage | 143 | P = 0.016 | P = 0.032 | P = 0.026 | P = 0.000 | P = 0.037 | P = 0.009 | ||||||
| I | 59 (41.3 %) | 36 (61.0 %) | 23 (39.0 %) | 36 (61.0 %) | 23 (39.0 %) | 23 (39.0 %) | 36 (61.0 %) | 42 (71.2 %) | 17 (28.8 %) | 37 (62.7 %) | 22 (37.3 %) | 22 (37.3 %) | 37 (62.7 %) |
| II | 36 (25.2 %) | 19 (52.8 %) | 17 (47.2 %) | 12 (33.3 %) | 24 (66.7 %) | 22 (61.1 %) | 14 (38.9 %) | 12 (33.3 %) | 24 (66.7 %) | 13 (36.1 %) | 23 (63.9 %) | 25 (69.4 %) | 11 (30.6 %) |
| III | 48 (33.6 %) | 16 (33.3 %) | 32 66.7 %) | 25 (52.1 %) | 23 (47.9 %) | 30 (62.5 %) | 18 (37.5 %) | 18 (37.5 %) | 30 (62.5 %) | 23 (47.9 %) | 25 (52.1 %) | 25 (52.1 %) | 23 (47.9 %) |
| CXCL14 | GMNN | INTS8 | MT1F | MT1G | SPRX | ||||||||
| High | Low | High | Low | High | Low | High | Low | High | Low | High | Low | ||
| Agea | 157 | P = 0.031 | P = 0.031 | P = 0.005 | P = 0.013 | P = 0.031 | P = 0.031 | ||||||
| < 65 | 80 (51.0 %) | 47 (58.8 %) | 33 (41.3 %) | 47 (58.8 %) | 33 (41.3 %) | 49 (61.2 %) | 31 (38.8 %) | 47 (58.8 %) | 32 (40.0 %) | 47 (58.8 %) | 33 (41.3 %) | 47 (58.8 %) | 33 (41.3 %) |
| ≥ 65 | 77 (49.0 %) | 32 (41.6 %) | 45 (58.4 %) | 32 (41.6 %) | 45 (58.4 %) | 30 (39.0 %) | 47 (61.0 %) | 32 (41.6 %) | 46 (59.7 %) | 32 (41.6 %) | 45 (58.4 %) | 32 (41.6 %) | 45 (58.4 %) |
| CLEC1B | CRHBP | FCN2 | MT1G | TBCE | |||||||||
| High | Low | High | Low | High | Low | High | Low | High | Low | ||||
| Gender | 157 | P = 0.003 | P = 0.019 | P = 0.043 | P = 0.003 | P = 0.019 | |||||||
| Female | 62 (39.5 %) | 22 (35.5 %) | 40 (64.5 %) | 24 (38.7 %) | 38 (61.3 %) | 25 (61.0 %) | 37 (39.0 %) | 22 (35.5 %) | 40 (64.5 %) | 24 (38.7 %) | 38 (61.3 %) | ||
| Male | 95 (60.5 %) | 57 (60.0 %) | 38 (40.0 %) | 55 (57.9 %) | 40 (42.1 %) | 54 (56.8 %) | 41 (43.2 %) | 57 (60.0 %) | 38 (40.0 %) | 55 (57.9 %) | 40 (42.1 %) | ||
aAge was dichotomised into < 65 and ≥ 65 using the median as a cutoff. PT, AJCC Tumour Pathologic PT. Expression values of a gene were dichotomised into high and low expression using the median as a cutoff. P value determined using Pearson’s χ2 test (2-sided)